Prasugrel, a Platelet P2Y <sub>12</sub> Receptor Antagonist, Improves Abnormal Gait in a Novel Murine Model of Thrombotic Hindlimb Ischemia
Kousaku Ohno(Sanin Rosai Hospital), Atsuhiro Sugidachi(Daiichi Sankyo (United Kingdom)), Makoto Mizuno(The University of Tokyo), Atsuyuki Tomizawa(Daiichi-Sankyo (Japan)), Joseph A. Jakubowski(Indiana Biosciences Research Institute)
Cited by 11
Related Papers
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617